A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy · Source last updated 2019-12-20
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
Units on a scale
Interval / dispersion
Standard Deviation
Time frame
Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
What was measured
EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Analysis population: The PP-ITT analysis set. Here, 'n' signifies those participants evaluated for this measure at specific time point for each group respectively. All 850 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.
Groups in this outcome
Docetaxel
Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
Atezolizumab
Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Docetaxel
425
Atezolizumab
425
Reported measurements
Nausea/Vomiting: Baseline (n= 389, 413)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
8.01
16.34
Not reported
Not reported
Not reported
Atezolizumab
7.59
16.35
Not reported
Not reported
Not reported
Nausea/Vomiting: C2D1(n= 342, 369)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.50
19.30
Not reported
Not reported
Not reported
Atezolizumab
9.53
17.25
Not reported
Not reported
Not reported
Nausea/Vomiting: C3D1(n= 253, 305)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
7.05
15.06
Not reported
Not reported
Not reported
Atezolizumab
7.27
15.32
Not reported
Not reported
Not reported
Nausea/Vomiting: C4D1(n= 223, 279)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
7.40
14.37
Not reported
Not reported
Not reported
Atezolizumab
7.17
15.50
Not reported
Not reported
Not reported
Nausea/Vomiting: C5D1(n= 167, 238)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.29
12.49
Not reported
Not reported
Not reported
Atezolizumab
6.44
14.54
Not reported
Not reported
Not reported
Nausea/Vomiting: C6D1(n= 151, 225)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.40
13.17
Not reported
Not reported
Not reported
Atezolizumab
6.44
15.16
Not reported
Not reported
Not reported
Nausea/Vomiting: C7D1(n= 88, 190)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.82
13.28
Not reported
Not reported
Not reported
Atezolizumab
5.61
13.74
Not reported
Not reported
Not reported
Nausea/Vomiting: C8D1(n= 72, 170)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.02
12.91
Not reported
Not reported
Not reported
Atezolizumab
4.61
10.57
Not reported
Not reported
Not reported
Nausea/Vomiting: C9D1(n= 50, 153)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
3.33
8.91
Not reported
Not reported
Not reported
Atezolizumab
2.83
8.06
Not reported
Not reported
Not reported
Nausea/Vomiting: C10D1(n= 47, 146)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
2.48
6.93
Not reported
Not reported
Not reported
Atezolizumab
3.54
10.02
Not reported
Not reported
Not reported
Nausea/Vomiting: C11D1(n= 37, 134)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
3.15
6.62
Not reported
Not reported
Not reported
Atezolizumab
3.23
8.54
Not reported
Not reported
Not reported
Nausea/Vomiting: C12D1(n= 30, 132)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
3.89
8.40
Not reported
Not reported
Not reported
Atezolizumab
3.03
7.66
Not reported
Not reported
Not reported
Nausea/Vomiting: C13D1(n= 19, 124)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
4.39
9.37
Not reported
Not reported
Not reported
Atezolizumab
3.36
10.19
Not reported
Not reported
Not reported
Nausea/Vomiting: C14D1(n= 18, 121)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
4.63
9.58
Not reported
Not reported
Not reported
Atezolizumab
3.31
9.03
Not reported
Not reported
Not reported
Nausea/Vomiting: C15D1(n= 16, 113)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
1.04
4.17
Not reported
Not reported
Not reported
Atezolizumab
3.83
11.14
Not reported
Not reported
Not reported
Nausea/Vomiting: C16D1(n= 13, 109)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
5.13
10.51
Not reported
Not reported
Not reported
Atezolizumab
2.75
8.64
Not reported
Not reported
Not reported
Nausea/Vomiting: C17D1(n= 11, 98)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
9.09
13.67
Not reported
Not reported
Not reported
Atezolizumab
2.55
8.06
Not reported
Not reported
Not reported
Nausea/Vomiting: C18D1(n= 10, 92)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.67
11.65
Not reported
Not reported
Not reported
Atezolizumab
3.08
8.88
Not reported
Not reported
Not reported
Nausea/Vomiting: C19D1(n= 9, 84)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
3.70
7.35
Not reported
Not reported
Not reported
Atezolizumab
4.17
11.53
Not reported
Not reported
Not reported
Nausea/Vomiting: C20D1(n= 9, 80)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
5.56
8.33
Not reported
Not reported
Not reported
Atezolizumab
3.13
11.28
Not reported
Not reported
Not reported
Nausea/Vomiting: C21D1(n= 9, 75)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
1.85
5.56
Not reported
Not reported
Not reported
Atezolizumab
4.89
13.08
Not reported
Not reported
Not reported
Nausea/Vomiting: C22D1(n= 8, 69)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.25
8.63
Not reported
Not reported
Not reported
Atezolizumab
1.93
7.31
Not reported
Not reported
Not reported
Nausea/Vomiting: C23D1(n= 8, 66)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
6.25
12.40
Not reported
Not reported
Not reported
Atezolizumab
2.53
6.69
Not reported
Not reported
Not reported
Nausea/Vomiting: C24D1(n= 5, 64)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
0.00
Not reported
Not reported
Not reported
Atezolizumab
2.34
7.19
Not reported
Not reported
Not reported
Nausea/Vomiting: C25D1(n= 3, 60)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
0.00
Not reported
Not reported
Not reported
Atezolizumab
1.94
6.21
Not reported
Not reported
Not reported
Nausea/Vomiting: C26D1(n= 3, 55)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
0.00
Not reported
Not reported
Not reported
Atezolizumab
2.73
8.34
Not reported
Not reported
Not reported
Nausea/Vomiting: C27D1(n= 3, 52)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
0.00
Not reported
Not reported
Not reported
Atezolizumab
2.24
6.62
Not reported
Not reported
Not reported
Nausea/Vomiting: C28D1(n= 1, 49)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
1.02
4.04
Not reported
Not reported
Not reported
Nausea/Vomiting: C29D1(n= 2, 40)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
33.33
47.14
Not reported
Not reported
Not reported
Atezolizumab
1.67
5.06
Not reported
Not reported
Not reported
Nausea/Vomiting: C30D1(n= 1, 31)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
1.61
5.01
Not reported
Not reported
Not reported
Nausea/Vomiting: C31D1(n= 0, 24)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
2.08
5.63
Not reported
Not reported
Not reported
Nausea/Vomiting: C32D1(n= 0, 22)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
1.52
4.90
Not reported
Not reported
Not reported
Nausea/Vomiting: C33D1(n= 0,16)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
1.04
4.17
Not reported
Not reported
Not reported
Nausea/Vomiting: C34D1(n= 0, 14)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
2.38
8.91
Not reported
Not reported
Not reported
Nausea/Vomiting: C35D1(n= 0, 12)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
1.39
4.81
Not reported
Not reported
Not reported
Nausea/Vomiting: C36D1(n= 0, 8)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
4.17
11.78
Not reported
Not reported
Not reported
Nausea/Vomiting: C37D1(n= 0, 5)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
6.67
9.13
Not reported
Not reported
Not reported
Nausea/Vomiting: C38D1(n= 0, 2)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
0.00
0.00
Not reported
Not reported
Not reported
Nausea/Vomiting: EOT(n= 266, 245)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.65
20.11
Not reported
Not reported
Not reported
Atezolizumab
10.61
17.62
Not reported
Not reported
Not reported
Nausea/Vomiting: Pro Week 6 Pd(n= 0,1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
16.67
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Nausea/Vomiting: Survival FU 1 (n= 2, 1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
50.00
70.71
Not reported
Not reported
Not reported
Atezolizumab
66.67
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Pain: Baseline (n= 390, 413)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
29.70
29.45
Not reported
Not reported
Not reported
Atezolizumab
29.98
29.72
Not reported
Not reported
Not reported
Pain: C2D1(n= 343, 368)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
28.43
27.24
Not reported
Not reported
Not reported
Atezolizumab
29.30
29.03
Not reported
Not reported
Not reported
Pain: C3D1(n= 256, 305)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.59
24.93
Not reported
Not reported
Not reported
Atezolizumab
24.15
27.50
Not reported
Not reported
Not reported
Pain: C4D1(n= 224, 280)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
21.65
24.48
Not reported
Not reported
Not reported
Atezolizumab
23.75
25.84
Not reported
Not reported
Not reported
Pain: C5D1(n= 167, 239)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
20.96
22.55
Not reported
Not reported
Not reported
Atezolizumab
23.22
25.41
Not reported
Not reported
Not reported
Pain: C6D1(n= 151, 225)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.41
21.95
Not reported
Not reported
Not reported
Atezolizumab
21.63
24.68
Not reported
Not reported
Not reported
Pain: C7D1(n= 88, 190)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
21.59
22.34
Not reported
Not reported
Not reported
Atezolizumab
21.58
25.30
Not reported
Not reported
Not reported
Pain: C8D1(n= 72, 171)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
23.38
22.49
Not reported
Not reported
Not reported
Atezolizumab
22.03
24.36
Not reported
Not reported
Not reported
Pain: C9D1(n= 50, 153)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
16.33
20.89
Not reported
Not reported
Not reported
Atezolizumab
19.28
23.50
Not reported
Not reported
Not reported
Pain: C10D1(n= 47, 146)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
14.54
17.93
Not reported
Not reported
Not reported
Atezolizumab
21.00
24.61
Not reported
Not reported
Not reported
Pain: C11D1(n= 37, 134)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
13.96
22.05
Not reported
Not reported
Not reported
Atezolizumab
21.27
26.60
Not reported
Not reported
Not reported
Pain: C12D1(n= 30, 132)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
13.33
21.17
Not reported
Not reported
Not reported
Atezolizumab
18.69
24.71
Not reported
Not reported
Not reported
Pain: C13D1(n= 19, 124)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
16.67
25.46
Not reported
Not reported
Not reported
Atezolizumab
17.74
21.23
Not reported
Not reported
Not reported
Pain: C14D1(n= 18, 120)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
12.04
15.97
Not reported
Not reported
Not reported
Atezolizumab
17.64
22.17
Not reported
Not reported
Not reported
Pain: C15D1(n= 16, 113)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
10.42
17.08
Not reported
Not reported
Not reported
Atezolizumab
17.40
22.86
Not reported
Not reported
Not reported
Pain: C16D1(n= 13, 109)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
21.79
21.93
Not reported
Not reported
Not reported
Atezolizumab
20.64
25.25
Not reported
Not reported
Not reported
Pain: C17D1(n= 11, 98)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
16.67
19.72
Not reported
Not reported
Not reported
Atezolizumab
20.41
25.39
Not reported
Not reported
Not reported
Pain: C18D1(n= 10, 92)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.67
22.29
Not reported
Not reported
Not reported
Atezolizumab
20.83
24.54
Not reported
Not reported
Not reported
Pain: C19D1(n= 9, 84)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
14.81
22.74
Not reported
Not reported
Not reported
Atezolizumab
22.42
28.16
Not reported
Not reported
Not reported
Pain: C20D1(n=9, 80)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
27.78
31.18
Not reported
Not reported
Not reported
Atezolizumab
20.00
23.78
Not reported
Not reported
Not reported
Pain: C21D1(n= 9, 75)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
14.81
17.57
Not reported
Not reported
Not reported
Atezolizumab
19.78
25.95
Not reported
Not reported
Not reported
Pain: C22D1(n= 8, 69)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
18.75
20.77
Not reported
Not reported
Not reported
Atezolizumab
15.22
19.75
Not reported
Not reported
Not reported
Pain: C23D1(n= 8, 66)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
14.58
27.37
Not reported
Not reported
Not reported
Atezolizumab
16.92
23.11
Not reported
Not reported
Not reported
Pain: C24D1(n=5, 64)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
30.00
36.13
Not reported
Not reported
Not reported
Atezolizumab
20.05
25.05
Not reported
Not reported
Not reported
Pain: C25D1(n= 3, 60)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
16.67
28.87
Not reported
Not reported
Not reported
Atezolizumab
18.33
22.90
Not reported
Not reported
Not reported
Pain: C26D1(n= 3, 55)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.22
19.24
Not reported
Not reported
Not reported
Atezolizumab
16.36
21.87
Not reported
Not reported
Not reported
Pain: C27D1(n= 3, 52)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.11
19.24
Not reported
Not reported
Not reported
Atezolizumab
15.06
20.41
Not reported
Not reported
Not reported
Pain: C28D1(n= 1, 49)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
14.29
18.63
Not reported
Not reported
Not reported
Pain: C29D1(n= 2, 40)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
41.67
58.93
Not reported
Not reported
Not reported
Atezolizumab
13.75
18.06
Not reported
Not reported
Not reported
Pain: C30D1(n= 1, 31)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
15.05
21.24
Not reported
Not reported
Not reported
Pain: C31D1(n= 0, 24)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
14.58
21.03
Not reported
Not reported
Not reported
Pain: C32D1(n= 0, 22)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
16.67
24.67
Not reported
Not reported
Not reported
Pain: C33D1(n= 0, 16)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
20.83
27.55
Not reported
Not reported
Not reported
Pain: C34D1(n= 0, 14)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
26.19
27.51
Not reported
Not reported
Not reported
Pain: C35D1(n= 0, 12)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
22.22
25.95
Not reported
Not reported
Not reported
Pain: C36D1(n= 0, 8)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
22.92
34.43
Not reported
Not reported
Not reported
Pain: C37D1(n= 0, 5)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
30.00
34.16
Not reported
Not reported
Not reported
Pain: C38D1(n= 0, 2)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
0.00
0.00
Not reported
Not reported
Not reported
Pain: EOT (n= 267, 247)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
32.21
30.36
Not reported
Not reported
Not reported
Atezolizumab
35.43
31.22
Not reported
Not reported
Not reported
Pain: Pro Week 6 Pd(n= 0,1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
16.67
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Pain: Survival FU-1 (n= 2,1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
66.67
47.14
Not reported
Not reported
Not reported
Atezolizumab
83.33
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Fatigue: Baseline (n= 390, 413)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
37.59
25.69
Not reported
Not reported
Not reported
Atezolizumab
36.21
23.92
Not reported
Not reported
Not reported
Fatigue: C2D1(n= 343, 369)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
40.52
25.68
Not reported
Not reported
Not reported
Atezolizumab
39.78
26.17
Not reported
Not reported
Not reported
Fatigue: C3D1(n= 256, 304)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
35.29
23.97
Not reported
Not reported
Not reported
Atezolizumab
33.90
23.75
Not reported
Not reported
Not reported
Fatigue: C4D1(n= 224, 278)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
35.59
23.10
Not reported
Not reported
Not reported
Atezolizumab
30.72
22.57
Not reported
Not reported
Not reported
Fatigue: C5D1(n= 167, 238)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
36.03
22.40
Not reported
Not reported
Not reported
Atezolizumab
30.95
24.13
Not reported
Not reported
Not reported
Fatigue: C6D1(n= 151, 225)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
36.28
23.40
Not reported
Not reported
Not reported
Atezolizumab
28.89
22.66
Not reported
Not reported
Not reported
Fatigue: C7D1(n= 88, 190)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
34.34
23.02
Not reported
Not reported
Not reported
Atezolizumab
28.33
22.15
Not reported
Not reported
Not reported
Fatigue: C8D1(n= 72, 170)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
30.86
24.12
Not reported
Not reported
Not reported
Atezolizumab
27.97
21.56
Not reported
Not reported
Not reported
Fatigue: C9D1(n= 50, 153)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
28.67
23.45
Not reported
Not reported
Not reported
Atezolizumab
25.78
21.39
Not reported
Not reported
Not reported
Fatigue: C10D1(n= 47, 145)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
29.31
25.21
Not reported
Not reported
Not reported
Atezolizumab
26.32
22.27
Not reported
Not reported
Not reported
Fatigue: C11D1(n= 37, 134)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
27.63
25.07
Not reported
Not reported
Not reported
Atezolizumab
25.62
23.05
Not reported
Not reported
Not reported
Fatigue: C12D1(n= 30, 132)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
28.89
23.99
Not reported
Not reported
Not reported
Atezolizumab
26.60
23.37
Not reported
Not reported
Not reported
Fatigue: C13D1(n= 19, 124)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.22
20.29
Not reported
Not reported
Not reported
Atezolizumab
27.51
22.73
Not reported
Not reported
Not reported
Fatigue: C14D1(n= 18, 121)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
21.60
16.82
Not reported
Not reported
Not reported
Atezolizumab
26.31
23.13
Not reported
Not reported
Not reported
Fatigue: C15D1(n= 16, 112)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
20.14
18.24
Not reported
Not reported
Not reported
Atezolizumab
27.73
22.56
Not reported
Not reported
Not reported
Fatigue: C16D1(n= 13, 109)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
21.79
17.64
Not reported
Not reported
Not reported
Atezolizumab
27.22
23.35
Not reported
Not reported
Not reported
Fatigue: C17D1(n= 11, 98)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.22
12.17
Not reported
Not reported
Not reported
Atezolizumab
27.21
23.56
Not reported
Not reported
Not reported
Fatigue: C18D1(n= 10, 92)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
26.67
17.53
Not reported
Not reported
Not reported
Atezolizumab
27.29
24.18
Not reported
Not reported
Not reported
Fatigue: C19D1(n= 9, 84)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.22
14.70
Not reported
Not reported
Not reported
Atezolizumab
27.65
22.85
Not reported
Not reported
Not reported
Fatigue: C20D1(n= 9, 80)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
32.10
30.15
Not reported
Not reported
Not reported
Atezolizumab
25.21
23.47
Not reported
Not reported
Not reported
Fatigue: C21D1(n= 9, 75)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
28.39
18.52
Not reported
Not reported
Not reported
Atezolizumab
26.44
23.66
Not reported
Not reported
Not reported
Fatigue: C22D1(n= 8, 69)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
33.33
29.10
Not reported
Not reported
Not reported
Atezolizumab
22.38
21.77
Not reported
Not reported
Not reported
Fatigue: C23D1(n= 8, 66)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
25.00
24.31
Not reported
Not reported
Not reported
Atezolizumab
24.16
20.59
Not reported
Not reported
Not reported
Fatigue: C24D1(n= 5, 64)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
31.11
40.37
Not reported
Not reported
Not reported
Atezolizumab
23.78
18.87
Not reported
Not reported
Not reported
Fatigue: C25D1(n= 3, 60)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.11
19.24
Not reported
Not reported
Not reported
Atezolizumab
23.89
20.94
Not reported
Not reported
Not reported
Fatigue: C26D1(n= 3, 55)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
18.52
16.97
Not reported
Not reported
Not reported
Atezolizumab
28.69
24.54
Not reported
Not reported
Not reported
Fatigue: C27D1(n= 3, 52)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
11.11
19.24
Not reported
Not reported
Not reported
Atezolizumab
22.65
19.80
Not reported
Not reported
Not reported
Fatigue: C28D1(n= 1, 49)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
0.00
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
22.34
18.23
Not reported
Not reported
Not reported
Fatigue: C29D1(n= 2, 40)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
44.44
47.14
Not reported
Not reported
Not reported
Atezolizumab
21.11
18.63
Not reported
Not reported
Not reported
Fatigue: C30D1(n= 1, 31)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
22.22
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab
23.66
20.23
Not reported
Not reported
Not reported
Fatigue: C31D1(n= 0, 24)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
23.15
20.96
Not reported
Not reported
Not reported
Fatigue: C32D1(n= 0, 22)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
25.25
20.63
Not reported
Not reported
Not reported
Fatigue: C33D1(n= 0, 16)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
29.86
26.52
Not reported
Not reported
Not reported
Fatigue: C34D1(n= 0, 14)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
31.75
24.21
Not reported
Not reported
Not reported
Fatigue: C35D1(n= 0, 12)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
25.00
21.25
Not reported
Not reported
Not reported
Fatigue: C36D1(n= 0, 8)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
16.67
15.71
Not reported
Not reported
Not reported
Fatigue: C37D1(n= 0, 5)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
24.44
16.48
Not reported
Not reported
Not reported
Fatigue: C38D1(n= 0, 2)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
16.67
7.86
Not reported
Not reported
Not reported
Fatigue: EOT(n= 267, 246)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
47.50
26.72
Not reported
Not reported
Not reported
Atezolizumab
43.07
28.15
Not reported
Not reported
Not reported
Fatigue: Pro Week 6 Pd(n= 0, 1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
NA
NA
Not reported
Not reported
Data not reported because no participant was evaluated for this category
Atezolizumab
44.44
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Fatigue: Survival FU-1 (n= 2, 1)
Values in Units on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Docetaxel
83.33
23.57
Not reported
Not reported
Not reported
Atezolizumab
88.89
NA
Not reported
Not reported
Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Complete source fields
classes
categories
measurements
group Id
OG000
spread
16.34
value
8.01
group Id
OG001
spread
16.35
value
7.59
title
Nausea/Vomiting: Baseline (n= 389, 413)
categories
measurements
group Id
OG000
spread
19.30
value
11.50
group Id
OG001
spread
17.25
value
9.53
title
Nausea/Vomiting: C2D1(n= 342, 369)
categories
measurements
group Id
OG000
spread
15.06
value
7.05
group Id
OG001
spread
15.32
value
7.27
title
Nausea/Vomiting: C3D1(n= 253, 305)
categories
measurements
group Id
OG000
spread
14.37
value
7.40
group Id
OG001
spread
15.50
value
7.17
title
Nausea/Vomiting: C4D1(n= 223, 279)
categories
measurements
group Id
OG000
spread
12.49
value
6.29
group Id
OG001
spread
14.54
value
6.44
title
Nausea/Vomiting: C5D1(n= 167, 238)
categories
measurements
group Id
OG000
spread
13.17
value
6.40
group Id
OG001
spread
15.16
value
6.44
title
Nausea/Vomiting: C6D1(n= 151, 225)
categories
measurements
group Id
OG000
spread
13.28
value
6.82
group Id
OG001
spread
13.74
value
5.61
title
Nausea/Vomiting: C7D1(n= 88, 190)
categories
measurements
group Id
OG000
spread
12.91
value
6.02
group Id
OG001
spread
10.57
value
4.61
title
Nausea/Vomiting: C8D1(n= 72, 170)
categories
measurements
group Id
OG000
spread
8.91
value
3.33
group Id
OG001
spread
8.06
value
2.83
title
Nausea/Vomiting: C9D1(n= 50, 153)
categories
measurements
group Id
OG000
spread
6.93
value
2.48
group Id
OG001
spread
10.02
value
3.54
title
Nausea/Vomiting: C10D1(n= 47, 146)
categories
measurements
group Id
OG000
spread
6.62
value
3.15
group Id
OG001
spread
8.54
value
3.23
title
Nausea/Vomiting: C11D1(n= 37, 134)
categories
measurements
group Id
OG000
spread
8.40
value
3.89
group Id
OG001
spread
7.66
value
3.03
title
Nausea/Vomiting: C12D1(n= 30, 132)
denoms
counts
group Id
OG000
value
425
group Id
OG001
value
425
units
Participants
description
EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
dispersion Type
Standard Deviation
groups
description
Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG000
title
Docetaxel
description
Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG001
title
Atezolizumab
param Type
MEAN
population Description
The PP-ITT analysis set. Here, 'n' signifies those participants evaluated for this measure at specific time point for each group respectively. All 850 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.
reporting Status
POSTED
time Frame
Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
Triangle